Full Press Release Details
REGENERON INITIATES PHASE II CLINICAL TRIAL OF IL1 TRAP IN PATIENTS WITH RHEUMATOID ARTHRITIS Lead Compound in Regeneron's Custom-designed Trap Program Advances in Clinic.
REGN
REGENERON INITIATES PHASE II CLINICAL TRIAL OF IL1 TRAP IN PATIENTS WITH RHEUMATOID ARTHRITIS Lead Compound in Regeneron's Custom-designed Trap Program Advances in Clinic
Key Takeaway: REGENERON INITIATES PHASE II CLINICAL TRIAL OF IL1 TRAP IN PATIENTS WITH RHEUMATOID ARTHRITIS Lead Compound in Regeneron's Custom-designed Trap Program Advances in Clinic
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema